<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0035-0052</journal-id>
<journal-title><![CDATA[Revista mexicana de pediatría]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. mex. pediatr.]]></abbrev-journal-title>
<issn>0035-0052</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Mexicana de Pediatría A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0035-00522021000600233</article-id>
<article-id pub-id-type="doi">10.35366/105425</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Evolución de paciente con mucopolisacaridosis tipo II que inició con idursulfasa a los tres años de edad]]></article-title>
<article-title xml:lang="en"><![CDATA[Evolution of a patient with type II mucopolysaccharidosis who started treatment with idursulfase at three years of age]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González-García]]></surname>
<given-names><![CDATA[Sofía Saraí]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Correa-González]]></surname>
<given-names><![CDATA[Lourdes Cecilia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García-Ortíz]]></surname>
<given-names><![CDATA[José Elías]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Mexicano del Seguro Social Hospital General de Zona No. 1 ]]></institution>
<addr-line><![CDATA[San Luis Potosí ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Mexicano del Seguro Social Hospital General de Zona No. 1 Departamento de Hematología Pediátrica]]></institution>
<addr-line><![CDATA[San Luis Potosí San Luis Potosí]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto Mexicano del Seguro Social División de Genética Centro Médico Nacional de Occidente]]></institution>
<addr-line><![CDATA[Guadalajara Jalisco]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<volume>88</volume>
<numero>6</numero>
<fpage>233</fpage>
<lpage>238</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0035-00522021000600233&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0035-00522021000600233&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0035-00522021000600233&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción:  La mucopolisacaridosis tipo II (MPS II) o síndrome de Hunter es una enfermedad lisosomal causada por la deficiencia de la enzima iduronato-2-sulfatasa, responsable de la degradación de los glucosaminoglucanos, sulfato de heparán y sulfato de dermatán.  Presentación del caso:  Paciente masculino con diagnóstico de MPS II a los tres años edad. El cuadro clínico incluía características faciales poco finas, esplenomegalia, limitación de la movilidad articular, infecciones de vías aéreas de repetición y retraso psicomotor. Se inició tratamiento con idursulfasa y, después de 24 meses, ha mejorado su crecimiento y la movilidad articular; además, disminuyó el volumen del bazo y no ha presentado infecciones respiratorias, pero los trastornos neurológicos persisten.  Conclusiones:  En la actualidad, la disponibilidad de idursulfasa, como terapia de reemplazo enzimático, ha mejorado el pronóstico de los pacientes con MPS II.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  Introduction:  Mucopolysaccharidosis type II (MPS II) or Hunter syndrome is a lysosomal disease caused by deficiency of the enzyme iduronate-2-sulfatase, responsible for the degradation of glycosaminoglycans.  Case presentation:  Male patient diagnosed with MPS II at three years of age. The clinical picture included coarse facial features, splenomegaly, limited joint mobility, recurrent airway infections, and psychomotor retardation. Treatment with idursulfase was started and, after 24 months, his growth and joint mobility have improved; in addition, the volume of the spleen decreased, and he has not presented respiratory infections, but the neurological disorders persist.  Conclusions:  Currently, the availability of idursulfase, as enzyme replacement therapy, has improved the prognosis of MPS II patients.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Mucopolisacaridosis II]]></kwd>
<kwd lng="es"><![CDATA[síndrome de Hunter]]></kwd>
<kwd lng="es"><![CDATA[iduronato-2-sulfatasa]]></kwd>
<kwd lng="es"><![CDATA[terapia de reemplazo enzimático]]></kwd>
<kwd lng="en"><![CDATA[Mucopolysaccharidosis II]]></kwd>
<kwd lng="en"><![CDATA[Hunter syndrome]]></kwd>
<kwd lng="en"><![CDATA[iduronate 2 sulfatase]]></kwd>
<kwd lng="en"><![CDATA[enzyme replacement therapy]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brusius-Facchin]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Schwartz]]></surname>
<given-names><![CDATA[IVD]]></given-names>
</name>
<name>
<surname><![CDATA[Zimmer]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ribeiro]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Acosta]]></surname>
<given-names><![CDATA[AX]]></given-names>
</name>
<name>
<surname><![CDATA[Horovitz]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mucopolysaccharidosis type II: Identification of 30 novel mutations among Latin American patients]]></article-title>
<source><![CDATA[Mol Genet Metab]]></source>
<year>2014</year>
<volume>111</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>133-8</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guffon]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Heron]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Chabrol]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Feillet]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Montauban]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Valayannopoulos]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: a retrospective observational study]]></article-title>
<source><![CDATA[Orphanet J Rare Dis]]></source>
<year>2015</year>
<volume>10</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-13</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stapleton]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kubaski]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Mason]]></surname>
<given-names><![CDATA[RW]]></given-names>
</name>
<name>
<surname><![CDATA[Yabe]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Suzuki]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Orii]]></surname>
<given-names><![CDATA[KE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Presentation and treatments for mucopolysaccharidosis type II]]></article-title>
<source><![CDATA[Expert Opin Orphan Drugs]]></source>
<year>2017</year>
<volume>5</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>295-307</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Acosta-gualandri]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mucopolisacaridosis II: nueva mutación patogénica en gen IDS]]></article-title>
<source><![CDATA[Acta Med Costarric]]></source>
<year>2014</year>
<volume>56</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>180-2</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mendoza-Ruvalcaba]]></surname>
<given-names><![CDATA[SDC]]></given-names>
</name>
<name>
<surname><![CDATA[Brambila-Tapia]]></surname>
<given-names><![CDATA[AJL]]></given-names>
</name>
<name>
<surname><![CDATA[Juárez-Osuna]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Da Silva-José]]></surname>
<given-names><![CDATA[TD]]></given-names>
</name>
<name>
<surname><![CDATA[García-Ortiz]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biochemical diagnosis of mucopolysaccharidosis in a Mexican reference center]]></article-title>
<source><![CDATA[Genet Mol Biol]]></source>
<year>2020</year>
<volume>43</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-5</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aparicio]]></surname>
<given-names><![CDATA[RJM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inborn errors of metabolism. Report of four cases with type I, II and VI mucopolysaccharidosis in three families]]></article-title>
<source><![CDATA[Revista Iberoamericana para la Investigación y el Desarrollo Docente]]></source>
<year>2007</year>
<volume>2</volume>
<page-range>189-208</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muenzer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Beck]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Eng]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Escolar]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Giugliani]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Guffon]]></surname>
<given-names><![CDATA[NH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multidisciplinary management of Hunter syndrome]]></article-title>
<source><![CDATA[Pediatrics]]></source>
<year>2009</year>
<volume>124</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>e1228-39</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wraith]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Scarpa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Beck]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bodamer]]></surname>
<given-names><![CDATA[OA]]></given-names>
</name>
<name>
<surname><![CDATA[De Meirleir]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Guffon]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mucopolysaccharidosis type II: a clinical review and recommendations for treatment in the era of enzyme replacement therapy]]></article-title>
<source><![CDATA[Eur J Pediatr]]></source>
<year>2008</year>
<volume>167</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>267-77</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Scarpa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mucopolysaccharidosis type II]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Adam]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Ardinger]]></surname>
<given-names><![CDATA[HH]]></given-names>
</name>
<name>
<surname><![CDATA[Pagon]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<source><![CDATA[GeneReviews® [Internet]]]></source>
<year>2007</year>
<publisher-loc><![CDATA[Seattle (WA) ]]></publisher-loc>
<publisher-name><![CDATA[University of Washington, Seattle]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Parody]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Guevara]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Aguirre]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tello]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost-effectiveness of the quantification of enzymatic activity in leukocytes in comparison to its nonrealization for a rare disease in Latin America: the case of mucopolysaccharidosis type II in Colombia]]></article-title>
<source><![CDATA[Value Heal Reg Issues]]></source>
<year>2016</year>
<volume>11</volume>
<numero>122</numero>
<issue>122</issue>
<page-range>42-8</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Whiteman]]></surname>
<given-names><![CDATA[DAH]]></given-names>
</name>
<name>
<surname><![CDATA[Kimura]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Development of idursulfase therapy for mucopolysaccharidosis type II: the past, the present and the future]]></article-title>
<source><![CDATA[Drug Des Devel Ther]]></source>
<year>2017</year>
<volume>11</volume>
<page-range>2467-80</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rivera]]></surname>
<given-names><![CDATA[VMR]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[VH]]></given-names>
</name>
<name>
<surname><![CDATA[Pacheco]]></surname>
<given-names><![CDATA[CG]]></given-names>
</name>
<name>
<surname><![CDATA[Cuevas-Covarrubias]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A case report of a patient with mucopolysaccharidosis type II]]></article-title>
<source><![CDATA[Rev Med Hosp Gen Méx]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kosuga]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mashima]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hirakiyama]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fuji]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Kumagai]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Seo]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Molecular diagnosis of 65 families with mucopolysaccharidosis type II characterized by 16 novel mutations in the IDS gene: Genetic, pathological, and structural studies on iduronate-2-sulfatase]]></article-title>
<source><![CDATA[Mol Genet Metab]]></source>
<year>2016</year>
<volume>118</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>190-7</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Whitley]]></surname>
<given-names><![CDATA[CB]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Aronovich]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
<name>
<surname><![CDATA[Crotty]]></surname>
<given-names><![CDATA[PL]]></given-names>
</name>
<name>
<surname><![CDATA[Anyane]]></surname>
<given-names><![CDATA[YK]]></given-names>
</name>
<name>
<surname><![CDATA[Russo]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Caveat to genotype-phenotype correlation in mucopolysaccharidosis type II: discordant clinical severity of R468W and R468Q mutations of the iduronate2-sulfatase gene]]></article-title>
<source><![CDATA[Hum Mutat]]></source>
<year>1993</year>
<volume>2</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>235-7</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moreira]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Kyosen]]></surname>
<given-names><![CDATA[SO]]></given-names>
</name>
<name>
<surname><![CDATA[Patti]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Martins]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Tufik]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of obstructive sleep apnea in patients with mucopolysaccharidosis types I, II, and VI in a reference center]]></article-title>
<source><![CDATA[Sleep Breath]]></source>
<year>2014</year>
<volume>18</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>791-7</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Giugliani]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hwu]]></surname>
<given-names><![CDATA[WL]]></given-names>
</name>
<name>
<surname><![CDATA[Tylki-Szymanska]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Whiteman]]></surname>
<given-names><![CDATA[DAH]]></given-names>
</name>
<name>
<surname><![CDATA[Pano]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A multicenter, open-label study evaluating safety and clinical outcomes in children (1.4-7.5 years) with Hunter syndrome receiving idursulfase enzyme replacement therapy]]></article-title>
<source><![CDATA[Genet Med]]></source>
<year>2014</year>
<volume>16</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>435-41</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[da Silva]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Strufaldi]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
<name>
<surname><![CDATA[Andriolo]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome)]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2016</year>
<volume>2</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>CD008185</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muenzer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Beck]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Giugliani]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Suzuki]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Tylki-Szymanska]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Valayannopoulos]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Idursulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter Outcome Survey]]></article-title>
<source><![CDATA[Genet Med]]></source>
<year>2011</year>
<volume>13</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>102-9</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tylki-Szymanska]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Jurecka]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Zuber]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Rozdzynska]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Marucha]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Czartoryska]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: a 3-year follow-up]]></article-title>
<source><![CDATA[Acta Paediatr Int J Paediatr]]></source>
<year>2012</year>
<volume>101</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>42-7</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muenzer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Botha]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Harmatz]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Giugliani]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kampmann]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Burton]]></surname>
<given-names><![CDATA[BK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation of the long-term treatment effects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling: data from the Hunter Outcome Survey (HOS)]]></article-title>
<source><![CDATA[Orphanet J Rare Dis]]></source>
<year>2021</year>
<volume>16</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>456</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Poswar]]></surname>
<given-names><![CDATA[FO]]></given-names>
</name>
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[ABS]]></given-names>
</name>
<name>
<surname><![CDATA[Berger]]></surname>
<given-names><![CDATA[SV]]></given-names>
</name>
<name>
<surname><![CDATA[de Souza]]></surname>
<given-names><![CDATA[CFM]]></given-names>
</name>
<name>
<surname><![CDATA[Giugliani]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Progression of cardiovascular manifestations in adults and children with mucopolysaccharidoses with and without enzyme replacement therapy]]></article-title>
<source><![CDATA[Front Cardiovasc Med]]></source>
<year>2022</year>
<volume>8</volume>
<page-range>801147</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
